In short
Ozanimod is a novel drug being investigated in clinical trials for the treatment of multiple sclerosis (MS) and ulcerative colitis (UC). This article summarizes key information about ongoing and completed clinical trials evaluating the efficacy, safety, and pharmacokinetics of ozanimod in these conditions. The trials aim to assess ozanimod's effects on disease activity, symptoms like fatigue, cognitive function, and quality of life in patients with MS and UC.
At a glance
- Conditions Studied
- Multiple Sclerosis, Ulcerative Colitis
- Main Outcomes
- Clinical remission, disease activity on MRI, fatigue, cognitive function
- Administration
- Oral capsules or tablets, once daily
- Special Populations
- Pediatric patients, patients with liver impairment
- Safety Assessments
- Adverse events, laboratory tests, vital signs
- Biomarkers
- Brain volume changes, neurofilament light, GFAP
- Quality of Life Measures
- Fatigue scales, cognitive assessments, patient-reported outcomes
What is Ozanimod?
Ozanimod is a medication that has been developed to treat certain autoimmune conditions. It's also known by its brand name Zeposia® and has been referred to in research as RPC1063 or BMS-986374. Ozanimod belongs to a class of drugs called sphingosine 1-phosphate (S1P) receptor modulators, which work by affecting the immune system.
What Conditions Does Ozanimod Treat?
Ozanimod has been studied and approved for use in treating two main conditions:
- Multiple Sclerosis (MS): Specifically, ozanimod is used for relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
- Ulcerative Colitis (UC): Ozanimod is also used to treat moderate to severe active ulcerative colitis in adults.
Both of these conditions are autoimmune diseases, where the body's immune system mistakenly attacks healthy tissues.
How Does Ozanimod Work?
Ozanimod works by modulating the immune system. It binds to specific receptors (S1P receptors) on immune cells, which prevents these cells from leaving the lymph nodes. This action reduces the number of immune cells circulating in the blood and entering the central nervous system (in MS) or the intestines (in UC). By doing so, ozanimod helps to decrease the inflammatory response that causes damage in these conditions.
How is Ozanimod Administered?
Ozanimod is taken orally in the form of capsules. The typical dosing schedule involves a gradual increase in dose over time:
- Days 1-4: 0.23 mg once daily
- Days 5-7: 0.46 mg once daily
- Day 8 and onwards: 0.92 mg once daily
This gradual increase helps to reduce the risk of certain side effects. It's important to take ozanimod exactly as prescribed by your healthcare provider.
Efficacy of Ozanimod
Clinical trials have shown promising results for ozanimod in both MS and UC:
- In MS, ozanimod has been found to reduce the rate of relapses and slow the progression of disability.
- For UC, studies have shown that ozanimod can help achieve and maintain clinical remission in patients with moderate to severe active disease.
Researchers are also investigating whether ozanimod might have positive effects on fatigue and cognitive function in MS patients.
Potential Side Effects
Like all medications, ozanimod can cause side effects. Some of the most common include:
- Upper respiratory infections
- Elevated liver enzymes
- Low blood pressure
- Back pain
- Headache
More serious but less common side effects can include increased risk of infections, changes in heart rhythm, and vision problems. It's important to discuss all potential risks with your healthcare provider.
Ongoing Research
Researchers continue to study ozanimod to better understand its effects and potential uses. Some areas of ongoing research include:
- Use in pediatric patients with ulcerative colitis
- Effects on fatigue and cognitive function in MS patients
- Development of new formulations, such as a granule formulation for patients who have difficulty swallowing capsules
- Long-term safety and efficacy in real-world clinical practice
These ongoing studies will help to further our understanding of ozanimod and potentially expand its use to benefit more patients.